ARA-290 (10MG)

Additional Info

Properties of ARA-290

• Chemical Formula: C51H84N16O21
• Molecular Weight: 1257.3 g/mol
• Sequence: ZEQLERALNSS
• Total Amount of Active Ingredient: 50 mg (1 vial)
• Shelf Life: 36 months

Shipping

• Available to USA and Canada.
• For international orders, there’s a provision for a 50% discount on the next purchase if the shipment is seized. Contact for further details.

Disclaimer

• The information provided is not a substitute for medical advice, diagnosis, or treatment. Consult a qualified healthcare provider for medical concerns.
• These research compounds are not FDA-approved for human consumption and are intended for research or laboratory use only.
• The product is not intended to diagnose, treat, cure, or prevent any disease.
• Follow specific research or laboratory protocols for usage.

Additional Label & Product Information:

Essential Warnings:

• Avoid skin and eye contact. Rinse with water thoroughly if contact occurs.
• Seek medical attention if feeling unwell or in case of accidental ingestion.
• Store the lyophilized peptide at room temperature upon receipt to maintain stability. Avoid frequent freeze-thaw cycles.

Product Disclaimer:

• This product is solely intended for research purposes and should be used only as directed by specific research or laboratory protocols.

Resources

• Brines, M., Dunne, A. N., van Velzen, M., Proto, P. L., Ostenson, C. G., Kirk, R. I., Petropoulos, I. N., Javed, S., Malik, R. A., Cerami, A., & Dahan, A. (2015). ARA-290, a peptide derived from erythropoietin but nonerythropoietic, enhances metabolic control and reduces neuropathic symptoms in individuals with type 2 diabetes. Molecular medicine (Cambridge, Mass.), 20(1), 658–666. Link
• Lois, N., Gardner, E., McFarland, M., Armstrong, D., McNally, C., Lavery, N. J., Campbell, C., Kirk, R. I., Bajorunas, D., Dunne, A., Cerami, A., & Brines, M. (2020). Phase 2 clinical trial assessing the efficacy of Cibinetide in treating diabetic macular edema. Journal of clinical medicine, 9(7), 2225. Link
• O’Leary, O. E., Canning, P., Reid, E., Bertelli, P. M., McKeown, S., Brines, M., Cerami, A., Du, X., Xu, H., Chen, M., Dutton, L., Brazil, D. P., Medina, R. J., & Stitt, A. W. (2019). Cibinetide, a non-hematopoietic erythropoietin mimic, enhances the vasoreparative potential of endothelial colony-forming cells in ischemic retina conditions. Experimental eye research, 182, 144–155. Link
• Watanabe, M., Lundgren, T., Saito, Y., Cerami, A., Brines, M., Östenson, C. G., & Kumagai-Braesch, M. (2016). ARA-290, a nonhematopoietic erythropoietin analogue, suppresses macrophage activation and protects transplanted islets from damage. Transplantation, 100(3), 554–562. Link
• Huang, B., Jiang, J., Luo, B., Zhu, W., Liu, Y., Wang, Z., & Zhang, Z. (2018). A non-erythropoietic peptide derived from erythropoietin protects mice from systemic lupus erythematosus. Journal of cellular and molecular medicine, 22(7), 3330–3339. Link
• Zhang, W., Yu, G., & Zhang, M. (2016). ARA-290 alleviates pathological pain by targeting the TRPV1 channel: Interplay between immune response and nociception. Peptides, 76, 73–79. Link